Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -4 of 4 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 1/1/1998


1.		Phase I/II Trial of Leuvectin as an Immunotherapeutic Agent by Direct Gene Transfer in Patients With Metastatic Melanoma, Renal Cell Carcinoma, and Sarcoma (Summary Last Modified 01/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Pharmaceutical / Industry				MAYO-960106 VCL-1102-102, NCI-G97-1282

Last Modified: 7/1/2002 First Published: 4/1/2000


2.		Phase I/II Study of Leuvectin in Patients With Locally Recurrent Organ-Confined Prostate Cancer After Radiotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-9906108 VCL-1102-203, NCI-G00-1721, NCT00005072

Last Modified: 7/1/2002 First Published: 10/1/1999


3.		Phase II Study of Neoadjuvant Leuvectin Followed by Retropubic Prostatectomy in Patients With Stage II or III Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-9901077-03B VCL-1102-202, NCI-G99-1568, NCT00004050


4.		A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				Pharmaceutical / Industry				IM01-101 NCT00223899

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute